Figure 2.
Role of m6A regulators in human metabolic diseases
Obesity mainly involves dysregulation of lipid metabolism, in which the expression of METTL3, METTL14, and WTAP are downregulated, while FTO is upregulated. In T2D, the expression of METTL14 is downregulated and FTO is upregulated in glucose metabolism, with increased expression of METTL3 in fatty acid metabolism. Metabolic disruption in human cancers mainly involves glycolysis and RNA metabolism. High METTL3 activates glycolysis to promote cancer development. The expression of FTO, METTL3, and YTHDF2 are high in the process of NAFLD. In osteoporosis, METTL3 expression is high, while FTO is low.